A McGivney Global Advisors op-ed on Oncology Value Metrics and ICER was referenced by the Biotechnology Industry Organization, quoting Jennifer Hinkel, MSc, Partner in her work on describing why ICER’s use of the QALY may lead to questionable decisions and, as a result, discriminatory rationing of cancer care.
"While using the QALY might be a nice academic exercise, its use becomes discriminatory when it’s used to ration care for particular groups of patients or prioritize spending." -Jennifer Hinkel, Partner @ McGA
BIO, along with other associations and a number of patient groups, have been critical of value metric approaches that may lead to rationing and discourage investment in new technologies, particularly because groups such as ICER seem to be targeting innovative, higher cost treatments for diseases such as Multiple Myeloma and Non-Small Cell Lung Cancer.
"Not only does this type of approach stifle innovation in the biopharma industry, but it also inevitably leads to healthcare rationing." -Jim Greenwood, CEO of Biotechnology Industry Organization (BIO)